Abstract: Lipid drug conjugate (LDC) is an active therapeutic agent for the combination of lipids such as fatty acids and phospholipids with drugs.It can be processed into nano-lipid drug conjugates, which can help to change the pharmacokinetic characteristics of the drug to achieve active targeted transport and reduce adverse reactions.The preparation methods, characterization measurements and applications of nano-lipid drug conjugates are summarized.
刘丽萍, 王煜斐, 张亚洲. 纳米脂质药物偶联物的研究进展[J]. 现代化工, 2018, 38(9): 50-53,55.
LIU Li-ping, WANG Yu-fei, ZHANG Ya-zhou. Research progress on lipid drug conjugate. Modern Chemical Industry, 2018, 38(9): 50-53,55.
[1] Koo O M,Rubinstein I,Onyuksel H.Role of nanotechnology in targeted drug delivery and imaging:A concise review[J].Nanomedicine Nanotechnology Biology & Medicine,2005,1(3):193-212. [2] 王彩霞,乌兰,郑源强.纳米药物在肺癌治疗中的研究进展[J].医学综述,2017,23(2):311-317. [3] 于莲,崔丹,应晓英.表面修饰脂质纳米粒给药系统的研究进展[J].中国现代应用药学,2011,28(2):108-112. [4] 宋春晓,何书莲,曹春凤.固体脂质纳米粒和纳米结构脂质载体在药物传递中的研究进展[J].药学研究,2016,35(4):234-236. [5] Battagli L,Gallarate M.Lipid nanoparticles:State of the art,new preparation methods and challenges in drug delivery[J].Expert Opinion on Drug Delivery,2012,9(5):497-508. [6] Wissing S A,Kayser O,Müller R H.Solid lipid nanoparticles for parenteral drug delivery[J].Advanced Drug Delivery Reviews,2004,56(9):1257-1272. [7] Müller R H.Colloidal carriers for controlled drug delivery and targeting:Modification,characterization,and in vivo distribution[B].1991:Wissenschaftliche Verlagsgesellschaft,CRC Press. [8] Patrícia S,Tatiana A,Sofia M A.Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery[J].Journal of drug delivery,2012:750891. [9] Lasasaracibar B,Estellahermoso D M A,Guada M.Lipid nanoparticles for cancer therapy:State of the art and future prospects[J].Expert Opinion on Drug Delivery,2012,9(10):1245-1261. [10] 苏君庆.PEG聚合物/脂质纳米粒的载体修饰、结构表征与体外性能[D].深圳:深圳大学,2016. [11] Neupane Y R,Sabir M D,Ahmad N.Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine:Ex vivo gut permeation studies[J].Nanotechnology,2013,24(41):415102. [12] 李欣玮,孙立新,林晓宏.固体脂质纳米粒作为药物载体[J].化学进展,2007,19(1):87-92. [13] 连佳芳,张三奇.固体脂质纳米粒研究进展[J].医学争鸣,2005,26(17):1621-1623. [14] Soni K,Kukereja B K,Kapur M.Lipid nanoparticles:Future of oral drug delivery and their current trends and regulatory issues[J].International Journal of Current Pharmaceutical Review and Research,2016,7(1):1-18. [15] Lu C T,Zhao Y Z,Wong H L.Current approaches to enhance CNS delivery of drugs across the brain barriers[J].International Journal of Nanomedicine,2014,9(1):2241-2257. [16] 胡本涛.DHA固体脂质纳米颗粒(SLN)制备、性质及应用[D].哈尔滨:东北农业大学,2013. [17] 吕文华.脂质纳米药物载体的制备与性质研究[D].上海:华东理工大学,2016. [18] Adhikari P,Pal P,Das A K.Nano lipid-drug conjugate:An integrated review[J].International Journal of Pharmaceutics,2017:629-641. [19] Lambert D M.Rationale and applications of lipids as prodrug carriers[J].European Journal of Pharmaceutical Sciences,2000,11(S2):S15-S27. [20] Mukherjee S,Ray S,Thakur R S.Solid lipid nanoparticles:A modern formulation approach in drug delivery system[J].Indian Journal of Pharmaceutical Sciences,2009,71(4):349-358. [21] Singh C,Bhatt T D,Gill M S.Novel rifampicin-phospholipid complex for tubercular therapy:Synthesis,physicochemical characterization and in-vivo evaluation[J].International Journal of Pharmaceutics,2014,460(1/2):220-227. [22] Semalty A,Semalty M,Singh D.Development and physicochemical evaluation of pharmacosomes of diclofenac[J].Acta Pharmaceutica,2009,59(3):335-344. [23] Olbrich C,Gessner A,Kayser O.Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate[J].Journal of Drug Targeting,2002,10(5):387-396. [24] Gasco M R.Solid lipid nanospheres from warm microemulsion[J].Pharm Echnol Eur,1997,1(9):52-58. [25] Del P A,Delgado D,Gascón A R.Lipid nanoparticles as drug/gene delivery systems to the retina[J].Journal of Ocular Pharmacology & Therapeutics the Official Journal of the Association for Ocular Pharmacology & Therapeutics,2013,29(2):173-188. [26] Olbrich C,Gessner A,Schröder W.Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption[J].Journal of Controlled Release,2004,96(3):425-435. [27] 黄瑞,郭盼,刘勃缨.藤黄酸纳米结构脂质载体的制备及抗肿瘤作用初步评价[J].天津中医药,2017,34(1):62-65. [28] 籍冰朔.尼莫地平纳米脂质体的制备及其抗帕金森症研究[D].秦皇岛:燕山大学,2016. [29] 宋宁,李颖寰.拉莫三嗪纳米脂质体的制备及脑靶向作用的研究[J].首都医科大学学报,2017,38(1):116-121. [30] 田振芬,吕文华,龚亚斌.蟾毒灵纳米结构脂质载体的制备及性质研究[J].化学通报,2017,80(7):679-683. [31] 卞龙艳.柚皮素固体脂质纳米粒制剂的制备、表征及药动学评价[J].中国新药杂志,2016,(12):1424-1430. [32] Dai Hualing,Gao Weiqi,Zhang Guoshun.Preparation of the nanostructured lipid carriers of artemisinin and its pharmacokinetic evalutation[J].Journal of Chinese Pharmaceutical Sciences,2017,(3):180-186.